Palliative care often arrives too late for hospitalized non-metastatic cancer patients

Hospitalized cancer patients without distant metastases are waiting longer than their metastatic counterparts for palliative care consultations, according to a large retrospective study from the Medical University of Vienna, and the delay may be costing them time, comfort, and hospital beds. The analysis, published in the journal Supportive Care in Cancer, examined 741 inpatients with solid organ tumors who received their first palliative care contact during an index hospitalization between 2016 and 2022, and its findings point to a systemic blind spot: clinicians appear to use metastatic status as a proxy for palliative need, even though patients with locally advanced but non-metastatic disease carry equally heavy burdens of symptoms, comorbidity, and mortality.

The study’s design was straightforward but methodologically rigorous. The researchers extracted structured data from the institutional database of University Hospital Vienna, capturing demographic characteristics, oncologic disease details, hospitalization records, and palliative care consultations. Patients with any prior contact with palliative care services, including outpatient consultations, were excluded, and each patient was counted only once to avoid intra-individual correlation from repeated admissions. Where database entries were incomplete or unclear, records were reviewed manually. The primary outcome was the interval from hospital admission to the first palliative care request; secondary endpoints included length of hospitalization, transfer to the in-hospital palliative care unit, in-hospital mortality, and overall survival from the time of cancer diagnosis. Time-to-event outcomes were evaluated with log-rank tests and Kaplan–Meier estimates, and Cox proportional hazards models were used to adjust for the presence of distant metastasis, age at hospitalization, and sex, with the proportional hazards assumption verified through log-minus-log survival plots.

Of the 741 inpatients included, 386, or 52.1 percent, had documented distant metastasis at the time of hospitalization. The two groups differed in ways that mattered for interpretation: the metastatic group contained a higher proportion of women (56.7 percent versus 44.8 percent), was younger at both diagnosis and admission, and had markedly different distributions of primary tumor sites. Among patients with metastatic disease, 59.8 percent had metastases confined to a single organ site, 26.7 percent had two metastatic sites, and 13.5 percent had generalized disease involving three or more sites. Interestingly, while the unadjusted Charlson Comorbidity Index was higher in the metastatic group, this was largely an artifact of the score’s weighting of metastatic cancer itself. When those points were excluded, patients with non-metastatic disease actually carried a higher non-cancer comorbidity burden, underscoring their substantial clinical complexity despite the absence of distant spread.

The central finding was a consistent timing gap. Patients with metastatic disease received their first palliative care consultation a median of seven days after admission, compared with nine days for patients with non-metastatic cancers, a statistically significant difference. Patients with non-metastatic disease were also less likely to be transferred to the specialized in-hospital palliative care unit, at 18.0 percent versus 24.6 percent. Early consultation, defined as a palliative care request within 72 hours of admission, was numerically less frequent in non-metastatic disease, at 16.9 percent versus 22.5 percent, a difference that just missed conventional significance thresholds. Perhaps most strikingly, fewer than a quarter of all patients in either group received palliative care involvement within that early window, suggesting that late consultation is the norm across the board, not merely a problem for one subgroup.

The consequences of delay were measurable. A palliative care consultation initiated within 72 hours of admission was associated with a significantly shorter hospital stay regardless of metastatic status. Among patients with non-metastatic disease who were discharged or transferred alive, those with early palliative involvement stayed a median of eight days, compared with 26 days for those consulted later. In the metastatic group, the corresponding figures were nine days versus twenty days. In Cox proportional hazards modeling, each day of delay in palliative care consultation was independently associated with longer hospitalization, with a hazard ratio of 0.966 for discharge, meaning the timing effect held after adjustment for metastatic status, age, sex, and the interval from admission to consultation. Metastatic status itself, by contrast, was not significantly associated with the length of hospital stay.

Mortality statistics add a sobering dimension to the timing question. Nearly half of all patients in the cohort died in hospital, with 49.2 percent of those with metastatic disease and 53.0 percent of those without dying during the index admission, a difference that was not statistically significant. Overall survival from diagnosis was longer in the metastatic group, a counterintuitive finding likely reflecting that these patients tended to be diagnosed earlier in their disease course relative to their palliative consultation, whereas non-metastatic patients arrived at palliative care sooner after diagnosis. The comparable mortality and the similar intervals from palliative consultation to death in both groups suggest, the authors argue, that the delayed involvement in non-metastatic patients cannot be explained by a more favorable prognosis and may instead reflect underutilization of palliative services in a population that needs them just as much.

The study’s authors probe the clinical reasoning behind the gap. Metastatic disease is widely regarded as incurable, and this clarity appears to act as a trigger for earlier goals-of-care discussions and palliative referrals. Non-metastatic disease, even when advanced, exists in a zone of therapeutic ambiguity: cure may still be possible in principle, yet acute deterioration or declining functional status can temporarily preclude disease-directed therapy. This uncertainty about prognosis and treatment intent, the researchers suggest, may cause clinicians to hesitate, postponing symptom management, psychosocial support, and advance care planning while options are weighed. The data argue against treating metastatic status as a reliable proxy for palliative need, since symptom burden, comorbidity, and mortality were comparable across both groups.

Beyond disease stage, the analysis surfaced an independent sex effect. Female sex was associated with earlier palliative care consultation, with a hazard ratio of 1.20, and with longer hospital stays. The researchers caution that their data cannot determine mechanism, but they point to prior literature suggesting that women may be more likely to report pain and emotional distress, potentially opening the door to supportive care discussions, while men may adopt more stoic or treatment-focused coping strategies that delay needs-based integration. Clinicians’ own perceptions of palliative need may also differ by sex, a phenomenon documented in studies of gender bias in pain estimation. Whatever the cause, the finding adds to a growing body of evidence that access to supportive services is not evenly distributed across patient groups.

The Vienna team situates its findings within a broader conceptual shift in the field, from “early” palliative care, defined by fixed time points after diagnosis, to “timely” palliative care, which is needs-based and responsive to individual patient trajectories. Professional guidelines, including the ASCO guideline update, recommend integrating palliative care early after diagnosis, ideally in the outpatient setting. But in practice, first contact with palliative services still frequently occurs during hospitalizations, often in response to acute deterioration. The study’s data reflect this reactive stage of care, in which consultation timing is driven by clinical events rather than systematically assessed needs. Hospitalization itself, the authors suggest, may represent a critical and underused moment for palliative integration, since many cancer patients are admitted during the final months of life and acute deterioration often signals a turning point in the disease trajectory.

There are also economic stakes. A substantial share of lifetime healthcare expenditures occurs in the final months of life, and prior research has shown that palliative care consultations initiated within two days of admission are linked to cost reductions of approximately 24 percent compared with no palliative involvement at all. The Vienna findings align with this literature: earlier consultation was associated with shorter stays, which in turn reduces resource use. The researchers emphasize that the association should not be read as causal, given the retrospective design and the possibility of residual confounding by indication. The study also relied on administrative data and could not capture symptom burden, psychosocial distress, treatment intent, or clinician referral practices, meaning it documents patterns of utilization rather than the appropriateness of individual referrals.

Still, the message is difficult to escape. In a cohort of more than 700 hospitalized cancer patients, roughly one in six to one in five received palliative care within the first 72 hours of admission, and those who did went home, or to other care settings, significantly sooner. Patients whose disease had not yet metastasized fared worst on every timing metric, despite comparable mortality and greater non-cancer comorbidity. The authors conclude that any hospital admission for a patient with cancer, regardless of stage, should prompt clinicians to reassess palliative needs, and they call for prospective studies to define clinical triggers for consultation rather than relying on oncologic milestones alone. As the field moves toward precision palliative care, the Vienna data serve as a reminder that the calendar of a patient’s disease is a poor substitute for the reality of their suffering.